HONG KONG – After eyeing biopharmaceuticals as a key area for breakthrough developments, China's State Council has released a roadmap for the manufacturing sector.
HONG KONG – Following the National Development and Reform Commission (NDRC)'s notice on removing the government price cap on most of the drugs in China, the government is slowly but gradually loosening its grip on drug prices. Large domestic pharmaceutical firms are most likely to benefit from that deregulation.
HONG KONG – Not only is China's biotech sector growing fast, but it is also changing rapidly. And those changes in its basic structure are appealing to Asia-focused biotech investors who gathered this week at Asia Biotech Invest 2015.
HONG KONG – With a focus on developing treatments for ocular fibrosis and inflammation, a new Australian biopharmaceutical company Occurx Pty Ltd. launched yesterday with A$6.5 million (US$5.2 million) in funds from a consortium that includes the Medical Research Commercialization Fund (MRCF), Brandon Capital Partners and Uniseed.
HONG KONG – With a focus on developing treatments for ocular fibrosis and inflammation, a new Australian biopharmaceutical company Occurx Pty Ltd. launched yesterday with A$6.5 million (US$5.2 million) in funds from a consortium that includes the Medical Research Commercialization Fund (MRCF), Brandon Capital Partners and Uniseed.
HONG KONG – South Korean drugmaker Celltrion Inc. has received marketing approval for its star product, Remsima, an infliximab biosimilar, in Brazil and Venezuela, marking the beginning of the company's expansion into Latin America.
HONG KONG – In a move that could lead to more and easier access to better medicines at the local level, China plans to eliminate fixed prices for drugs next month. And, despite public concerns, the regulator said drug prices will not shoot up even after price caps are taken away.
HONG KONG – With a third round of funding in hand, Taiwanese contract manufacturer and biosimilars maker JHL Biotech Inc. is that much closer to its first filing in Europe and an IPO later this year.
HONG KONG – With a third round of funding in hand, Taiwanese contract manufacturer and biosimilars maker JHL Biotech Inc. is that much closer to its first filing in Europe and an IPO later this year.
HONG KONG – In a move that could lead to more and easier access to better medicines at the local level, China plans to eliminate fixed prices for drugs next month. And, despite public concerns, the regulator said drug prices will not shoot up even after price caps are taken away.
